메뉴 건너뛰기




Volumn 19, Issue 12, 2005, Pages 2177-2185

Growth factors and antiapoptotic signaling pathways in multiple myeloma

Author keywords

Apoptosis; Drug resistance; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; APOPTOSIS INHIBITOR; BORTEZOMIB; CELL ADHESION MOLECULE; CYTOKINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVALONIC ACID; MONOCLONAL ANTIBODY; OBLIMERSEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; RAPAMYCIN; RAS PROTEIN; SOMATOMEDIN C; STAT3 PROTEIN; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

EID: 28544437352     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403970     Document Type: Review
Times cited : (59)

References (100)
  • 1
    • 0037169358 scopus 로고    scopus 로고
    • Apoptosis: A link between cancer genetics and chemotherapy
    • Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
    • (2002) Cell , vol.108 , pp. 153-164
    • Johnstone, R.W.1    Ruefli, A.A.2    Lowe, S.W.3
  • 2
    • 0033105537 scopus 로고    scopus 로고
    • Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
    • Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
    • (1999) Blood , vol.93 , pp. 1658-1667
    • Damiano, J.S.1    Cress, A.E.2    Hazlehurst, L.A.3    Shtil, A.A.4    Dalton, W.S.5
  • 3
    • 10744227500 scopus 로고    scopus 로고
    • Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    • Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003; 63: 7900-7906.
    • (2003) Cancer Res. , vol.63 , pp. 7900-7906
    • Hazlehurst, L.A.1    Enkemann, S.A.2    Beam, C.A.3    Argilagos, R.F.4    Painter, J.5    Shain, K.H.6
  • 4
    • 0036839144 scopus 로고    scopus 로고
    • In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway
    • Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002; 100: 3311-3318.
    • (2002) Blood , vol.100 , pp. 3311-3318
    • Chatterjee, M.1    Honemann, D.2    Lentzsch, S.3    Bommert, K.4    Sers, C.5    Herrmann, P.6
  • 5
    • 0038717067 scopus 로고    scopus 로고
    • Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms
    • Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175-1182.
    • (2003) Leukemia , vol.17 , pp. 1175-1182
    • Nefedova, Y.1    Landowski, T.H.2    Dalton, W.S.3
  • 6
    • 4444282702 scopus 로고    scopus 로고
    • The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase
    • Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004; 104: 1825-1832.
    • (2004) Blood , vol.104 , pp. 1825-1832
    • Schmidmaier, R.1    Baumann, P.2    Simsek, M.3    Dayyani, F.4    Emmerich, B.5    Meinhardt, G.6
  • 7
    • 0028101292 scopus 로고
    • Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures
    • Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269-2277.
    • (1994) Blood , vol.84 , pp. 2269-2277
    • Lokhorst, H.M.1    Lamme, T.2    de Smet, M.3    Klein, S.4    de Weger, R.A.5    van Oers, R.6
  • 8
    • 0030041147 scopus 로고    scopus 로고
    • Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
    • Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104-1112.
    • (1996) Blood , vol.87 , pp. 1104-1112
    • Chauhan, D.1    Uchiyama, H.2    Akbarali, Y.3    Urashima, M.4    Yamamoto, K.5    Libermann, T.A.6
  • 9
    • 9444269817 scopus 로고    scopus 로고
    • Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines
    • Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004; 104: 3697-3704.
    • (2004) Blood , vol.104 , pp. 3697-3704
    • Houde, C.1    Li, Y.2    Song, L.3    Barton, K.4    Zhang, Q.5    Godwin, J.6
  • 10
    • 0034655957 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
    • Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636.
    • (2000) Blood , vol.95 , pp. 2630-2636
    • Dankbar, B.1    Padro, T.2    Leo, R.3    Feldmann, B.4    Kropff, M.5    Mesters, R.M.6
  • 11
    • 0038446643 scopus 로고    scopus 로고
    • Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
    • Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101: 2775-2783.
    • (2003) Blood , vol.101 , pp. 2775-2783
    • Bisping, G.1    Leo, R.2    Wenning, D.3    Dankbar, B.4    Padro, T.5    Kropff, M.6
  • 12
    • 0035863942 scopus 로고    scopus 로고
    • Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis
    • Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483-489.
    • (2001) Blood , vol.97 , pp. 483-489
    • Frassanito, M.A.1    Cusmai, A.2    Iodice, G.3    Dammacco, F.4
  • 13
  • 14
    • 9144231336 scopus 로고    scopus 로고
    • Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
    • Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Loffler D, Koczan D et al. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 2004; 103: 242-251.
    • (2004) Blood , vol.103 , pp. 242-251
    • Brocke-Heidrich, K.1    Kretzschmar, A.K.2    Pfeifer, G.3    Henze, C.4    Loffler, D.5    Koczan, D.6
  • 15
    • 0031225483 scopus 로고    scopus 로고
    • IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
    • Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212-2221.
    • (1997) J. Immunol. , vol.159 , pp. 2212-2221
    • Ogata, A.1    Chauhan, D.2    Teoh, G.3    Treon, S.P.4    Urashima, M.5    Schlossman, R.L.6
  • 16
    • 0034548453 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses
    • Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763-6770.
    • (2000) Cancer Res. , vol.60 , pp. 6763-6770
    • Tu, Y.1    Gardner, A.2    Lichtenstein, A.3
  • 17
    • 0032984589 scopus 로고    scopus 로고
    • Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    • Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
    • (1999) Immunity , vol.10 , pp. 105-115
    • Catlett-Falcone, R.1    Landowski, T.H.2    Oshiro, M.M.3    Turkson, J.4    Levitzki, A.5    Savino, R.6
  • 18
    • 0035921689 scopus 로고    scopus 로고
    • Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
    • Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991-6000.
    • (2001) Oncogene , vol.20 , pp. 5991-6000
    • Hideshima, T.1    Nakamura, N.2    Chauhan, D.3    Anderson, K.C.4
  • 19
    • 0035678875 scopus 로고    scopus 로고
    • Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells
    • Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 2001; 7: 4262-4271.
    • (2001) Clin. Cancer Res. , vol.7 , pp. 4262-4271
    • Oshiro, M.M.1    Landowski, T.H.2    Catlett-Falcone, R.3    Hazlehurst, L.A.4    Huang, M.5    Jove, R.6
  • 20
    • 0034531866 scopus 로고    scopus 로고
    • Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway
    • Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626-634.
    • (2000) Br. J. Haematol. , vol.111 , pp. 626-634
    • Ferlin, M.1    Noraz, N.2    Hertogh, C.3    Brochier, J.4    Taylor, N.5    Klein, B.6
  • 21
    • 1542343942 scopus 로고    scopus 로고
    • Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor alpha myeloma cells
    • Abroun S, Ishikawa H, Tsuyama N, Liu S, Li FJ, Otsuyama K et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor alpha myeloma cells. Blood 2004; 103: 2291-2298.
    • (2004) Blood , vol.103 , pp. 2291-2298
    • Abroun, S.1    Ishikawa, H.2    Tsuyama, N.3    Liu, S.4    Li, F.J.5    Otsuyama, K.6
  • 22
    • 0036625066 scopus 로고    scopus 로고
    • Insulinlike growth factor-I signaling in multiple myeloma: Downstream elements, functional correlates, and pathway cross-talk
    • Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: Downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 4138-4146.
    • (2002) Blood , vol.99 , pp. 4138-4146
    • Qiang, Y.W.1    Kopantzev, E.2    Rudikoff, S.3
  • 23
    • 0037158513 scopus 로고    scopus 로고
    • Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications
    • Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002; 21: 5673-5683.
    • (2002) Oncogene , vol.21 , pp. 5673-5683
    • Mitsiades, C.S.1    Mitsiades, N.2    Poulaki, V.3    Schlossman, R.4    Akiyama, M.5    Chauhan, D.6
  • 24
    • 0025771283 scopus 로고
    • Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells
    • Abboud SL, Bethel CR, Aron DC. Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest 1991; 88: 470-475.
    • (1991) J. Clin. Invest. , vol.88 , pp. 470-475
    • Abboud, S.L.1    Bethel, C.R.2    Aron, D.C.3
  • 25
    • 3843051264 scopus 로고    scopus 로고
    • Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
    • Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 104: 1159-1165.
    • (2004) Blood , vol.104 , pp. 1159-1165
    • Kumar, S.1    Witzig, T.E.2    Timm, M.3    Haug, J.4    Wellik, L.5    Kimlinger, T.K.6
  • 27
    • 8844219644 scopus 로고    scopus 로고
    • PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells
    • Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004; 18: 1883-1890.
    • (2004) Leukemia , vol.18 , pp. 1883-1890
    • Lentzsch, S.1    Chatterjee, M.2    Gries, M.3    Bommert, K.4    Gollasch, H.5    Dorken, B.6
  • 28
    • 6944253220 scopus 로고    scopus 로고
    • VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
    • Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004; 104: 2886-2892.
    • (2004) Blood , vol.104 , pp. 2886-2892
    • Le Gouill, S.1    Podar, K.2    Amiot, M.3    Hideshima, T.4    Chauhan, D.5    Ishitsuka, K.6
  • 29
    • 0036731996 scopus 로고    scopus 로고
    • The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment
    • Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002; 62: 5019-5026.
    • (2002) Cancer Res. , vol.62 , pp. 5019-5026
    • Lin, B.1    Podar, K.2    Gupta, D.3    Tai, Y.T.4    Li, S.5    Weller, E.6
  • 30
    • 11144354204 scopus 로고    scopus 로고
    • GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment
    • Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004; 103: 3474-3479.
    • (2004) Blood , vol.103 , pp. 3474-3479
    • Podar, K.1    Catley, L.P.2    Tai, Y.T.3    Shringarpure, R.4    Carvalho, P.5    Hayashi, T.6
  • 31
    • 0038369758 scopus 로고    scopus 로고
    • Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells
    • Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003; 22: 2417-2421.
    • (2003) Oncogene , vol.22 , pp. 2417-2421
    • Landowski, T.H.1    Olashaw, N.E.2    Agrawal, D.3    Dalton, W.S.4
  • 32
    • 4644357296 scopus 로고    scopus 로고
    • Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis
    • Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004; 104: 2149-2154.
    • (2004) Blood , vol.104 , pp. 2149-2154
    • Mori, Y.1    Shimizu, N.2    Dallas, M.3    Niewolna, M.4    Story, B.5    Williams, P.J.6
  • 33
    • 1942425110 scopus 로고    scopus 로고
    • Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
    • Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004; 103: 3503-3510.
    • (2004) Blood , vol.103 , pp. 3503-3510
    • Nefedova, Y.1    Cheng, P.2    Alsina, M.3    Dalton, W.S.4    Gabrilovich, D.I.5
  • 34
    • 0037069943 scopus 로고    scopus 로고
    • Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: Implications for disease progression and therapeutic response
    • Rowley M, Van Ness B. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: Implications for disease progression and therapeutic response. Oncogene 2002; 21: 8769-8775.
    • (2002) Oncogene , vol.21 , pp. 8769-8775
    • Rowley, M.1    Van Ness, B.2
  • 35
    • 0038281345 scopus 로고    scopus 로고
    • Downstream effectors of oncogenic ras in multiple myeloma cells
    • Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101: 3126-3135.
    • (2003) Blood , vol.101 , pp. 3126-3135
    • Hu, L.1    Shi, Y.2    Hsu, J.H.3    Gera, J.4    Van Ness, B.5    Lichtenstein, A.6
  • 36
    • 0029819604 scopus 로고    scopus 로고
    • Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial
    • Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996; 88: 2699-2706.
    • (1996) Blood , vol.88 , pp. 2699-2706
    • Liu, P.1    Leong, T.2    Quam, L.3    Billadeau, D.4    Kay, N.E.5    Greipp, P.6
  • 38
  • 39
    • 0030926355 scopus 로고    scopus 로고
    • Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6
    • Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res 1997; 57: 2268-2275.
    • (1997) Cancer Res. , vol.57 , pp. 2268-2275
    • Billadeau, D.1    Liu, P.2    Jelinek, D.3    Shah, N.4    LeBien, T.W.5    Van Ness, B.6
  • 40
    • 0034332169 scopus 로고    scopus 로고
    • Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan
    • Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood 2000; 96: 3175-3180.
    • (2000) Blood , vol.96 , pp. 3175-3180
    • Rowley, M.1    Liu, P.2    Van Ness, B.3
  • 41
    • 0033121314 scopus 로고    scopus 로고
    • Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2
    • Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044-3052.
    • (1999) Blood , vol.93 , pp. 3044-3052
    • Feinman, R.1    Koury, J.2    Thames, M.3    Barlogie, B.4    Epstein, J.5    Siegel, D.S.6
  • 42
    • 0037305821 scopus 로고    scopus 로고
    • Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis
    • Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053-1062.
    • (2003) Blood , vol.101 , pp. 1053-1062
    • Bharti, A.C.1    Donato, N.2    Singh, S.3    Aggarwal, B.B.4
  • 43
    • 1842579486 scopus 로고    scopus 로고
    • Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
    • Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103: 3175-3184.
    • (2004) Blood , vol.103 , pp. 3175-3184
    • Bharti, A.C.1    Shishodia, S.2    Reuben, J.M.3    Weber, D.4    Alexanian, R.5    Raj-Vadhan, S.6
  • 44
    • 0037097595 scopus 로고    scopus 로고
    • Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications
    • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002; 99: 4525-4530.
    • (2002) Blood , vol.99 , pp. 4525-4530
    • Mitsiades, N.1    Mitsiades, C.S.2    Poulaki, V.3    Chauhan, D.4    Richardson, P.G.5    Hideshima, T.6
  • 46
    • 0036624741 scopus 로고    scopus 로고
    • Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications
    • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 2002; 99: 4079-4086.
    • (2002) Blood , vol.99 , pp. 4079-4086
    • Mitsiades, N.1    Mitsiades, C.S.2    Poulaki, V.3    Chauhan, D.4    Richardson, P.G.5    Hideshima, T.6
  • 47
    • 0035958517 scopus 로고    scopus 로고
    • The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications
    • Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001; 20: 4519-4527.
    • (2001) Oncogene , vol.20 , pp. 4519-4527
    • Hideshima, T.1    Chauhan, D.2    Schlossman, R.3    Richardson, P.4    Anderson, K.C.5
  • 49
    • 0035525792 scopus 로고    scopus 로고
    • The AKT kinase is activated in multiple myeloma tumor cells
    • Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853-2855.
    • (2001) Blood , vol.98 , pp. 2853-2855
    • Hsu, J.1    Shi, Y.2    Krajewski, S.3    Renner, S.4    Fisher, M.5    Reed, J.C.6
  • 50
    • 0034669945 scopus 로고    scopus 로고
    • Loss of PTEN expression leading to high Akt activation in human multiple myelomas
    • Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000; 96: 3560-3568.
    • (2000) Blood , vol.96 , pp. 3560-3568
    • Hyun, T.1    Yam, A.2    Pece, S.3    Xie, X.4    Zhang, J.5    Miki, T.6
  • 51
    • 0037013205 scopus 로고    scopus 로고
    • Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6
    • Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem 2002; 277: 15712-15720.
    • (2002) J. Biol. Chem. , vol.277 , pp. 15712-15720
    • Shi, Y.1    Hsu, J.H.2    Hu, L.3    Gera, J.4    Lichtenstein, A.5
  • 52
    • 17444440115 scopus 로고    scopus 로고
    • Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
    • Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004; 103: 3138-3147.
    • (2004) Blood , vol.103 , pp. 3138-3147
    • Stromberg, T.1    Dimberg, A.2    Hammarberg, A.3    Carlson, K.4    Osterborg, A.5    Nilsson, K.6
  • 53
    • 0032711250 scopus 로고    scopus 로고
    • IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway
    • Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999; 29: 3945-3950.
    • (1999) Eur. J. Immunol. , vol.29 , pp. 3945-3950
    • Puthier, D.1    Bataille, R.2    Amiot, M.3
  • 54
    • 0038784365 scopus 로고    scopus 로고
    • SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma
    • Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101: 2784-2788.
    • (2003) Blood , vol.101 , pp. 2784-2788
    • Galm, O.1    Yoshikawa, H.2    Esteller, M.3    Osieka, R.4    Herman, J.G.5
  • 55
    • 2942584857 scopus 로고    scopus 로고
    • SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway
    • Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway. Blood 2004; 103: 4630-4635.
    • (2004) Blood , vol.103 , pp. 4630-4635
    • Chim, C.S.1    Fung, T.K.2    Cheung, W.C.3    Liang, R.4    Kwong, Y.L.5
  • 56
    • 0037236924 scopus 로고    scopus 로고
    • Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis
    • Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326.
    • (2003) Clin. Cancer Res. , vol.9 , pp. 316-326
    • Alas, S.1    Bonavida, B.2
  • 57
    • 0033179760 scopus 로고    scopus 로고
    • BCL-2 family members and the mitochondria in apoptosis
    • Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
    • (1999) Genes Dev. , vol.13 , pp. 1899-1911
    • Gross, A.1    McDonnell, J.M.2    Korsmeyer, S.J.3
  • 58
    • 0028886023 scopus 로고
    • Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein
    • Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, Mellstedt H et al. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995; 63: 190-192.
    • (1995) Int. J. Cancer , vol.63 , pp. 190-192
    • Sangfelt, O.1    Osterborg, A.2    Grander, D.3    Anderbring, E.4    Ost, A.5    Mellstedt, H.6
  • 61
    • 0037212602 scopus 로고    scopus 로고
    • Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma
    • Iyer R, Ding L, Batchu RB, Naugler S, Shammas MA, Munshi NC. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leuk Res 2003; 27: 73-78.
    • (2003) Leuk. Res. , vol.27 , pp. 73-78
    • Iyer, R.1    Ding, L.2    Batchu, R.B.3    Naugler, S.4    Shammas, M.A.5    Munshi, N.C.6
  • 62
    • 0025939204 scopus 로고
    • Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease
    • Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661-8665.
    • (1991) Proc. Natl. Acad. Sci. USA , vol.88 , pp. 8661-8665
    • Strasser, A.1    Whittingham, S.2    Vaux, D.L.3    Bath, M.L.4    Adams, J.M.5    Cory, S.6
  • 63
    • 0027461627 scopus 로고
    • E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells
    • Strasser A, Harris AW, Cory S. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 1993; 8: 1-9.
    • (1993) Oncogene , vol.8 , pp. 1-9
    • Strasser, A.1    Harris, A.W.2    Cory, S.3
  • 64
    • 0026688162 scopus 로고
    • Apoptotic cell death induced by c-myc is inhibited by bcl-2
    • Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-554.
    • (1992) Nature , vol.359 , pp. 552-554
    • Bissonnette, R.P.1    Echeverri, F.2    Mahboubi, A.3    Green, D.R.4
  • 65
    • 0029794419 scopus 로고    scopus 로고
    • Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide
    • Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C et al. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996; 88: 1805-1812.
    • (1996) Blood , vol.88 , pp. 1805-1812
    • Tu, Y.1    Xu, F.H.2    Liu, J.3    Vescio, R.4    Berenson, J.5    Fady, C.6
  • 66
    • 0037113881 scopus 로고    scopus 로고
    • Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin
    • Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002; 277: 44317-44326.
    • (2002) J. Biol. Chem. , vol.277 , pp. 44317-44326
    • Panaretakis, T.1    Pokrovskaja, K.2    Shoshan, M.C.3    Grander, D.4
  • 68
    • 0029002318 scopus 로고
    • Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL
    • Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995; 55: 2262-2265.
    • (1995) Cancer Res. , vol.55 , pp. 2262-2265
    • Schwarze, M.M.1    Hawley, R.G.2
  • 69
    • 0037265811 scopus 로고    scopus 로고
    • Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein
    • van de Donk NW, Kamphuis MM, Van Dijk M, Borst HP, Bloem AC, Lokhorst HM. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17: 211-219.
    • (2003) Leukemia , vol.17 , pp. 211-219
    • van de Donk, N.W.1    Kamphuis, M.M.2    Van Dijk, M.3    Borst, H.P.4    Bloem, A.C.5    Lokhorst, H.M.6
  • 70
    • 0036659905 scopus 로고    scopus 로고
    • Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells
    • Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-199.
    • (2002) Blood , vol.100 , pp. 194-199
    • Derenne, S.1    Monia, B.2    Dean, N.M.3    Taylor, J.K.4    Rapp, M.J.5    Harousseau, J.L.6
  • 71
    • 0142244338 scopus 로고    scopus 로고
    • The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells
    • Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003; 17: 2036-2045.
    • (2003) Leukemia , vol.17 , pp. 2036-2045
    • Pei, X.Y.1    Dai, Y.2    Grant, S.3
  • 72
    • 2942666279 scopus 로고    scopus 로고
    • G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma
    • van de Donk NW, De Weerdt O, Veth G, Eurelings M, van Stralen E, Frankel SR et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 2004; 18: 1078-1084.
    • (2004) Leukemia , vol.18 , pp. 1078-1084
    • van de Donk, N.W.1    De Weerdt, O.2    Veth, G.3    Eurelings, M.4    van Stralen, E.5    Frankel, S.R.6
  • 73
    • 23044452536 scopus 로고    scopus 로고
    • Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    • Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005; 23: 4089-4099.
    • (2005) J. Clin. Oncol. , vol.23 , pp. 4089-4099
    • Badros, A.Z.1    Goloubeva, O.2    Rapoport, A.P.3    Ratterree, B.4    Gahres, N.5    Meisenberg, B.6
  • 74
    • 20444435635 scopus 로고    scopus 로고
    • Randomized multicenter phase 3 trial of high-dose dexamethasone (dex) with or without oblimersen sodium (G3139; Bcl-2 antisense; Genasense) for patients with advanced multiple myeloma (MM)
    • Chanan-Khan A, Niesvisky R, Hohl R, Zimmerman T, Christiansen N, Schiller G et al. Randomized multicenter phase 3 trial of high-dose dexamethasone (dex) with or without oblimersen sodium (G3139; Bcl-2 antisense; Genasense) for patients with advanced multiple myeloma (MM). Blood 2004; 104: 1477a.
    • (2004) Blood , vol.104
    • Chanan-Khan, A.1    Niesvisky, R.2    Hohl, R.3    Zimmerman, T.4    Christiansen, N.5    Schiller, G.6
  • 75
    • 0034212785 scopus 로고    scopus 로고
    • Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
    • Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-3071.
    • (2000) Cancer Res. , vol.60 , pp. 3065-3071
    • Park, W.H.1    Seol, J.G.2    Kim, E.S.3    Hyun, J.M.4    Jung, C.W.5    Lee, C.C.6
  • 77
    • 0037111779 scopus 로고    scopus 로고
    • Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance
    • Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 2002; 100: 3819-3821.
    • (2002) Blood , vol.100 , pp. 3819-3821
    • Pollett, J.B.1    Trudel, S.2    Stern, D.3    Li, Z.H.4    Stewart, A.K.5
  • 78
    • 3042806890 scopus 로고    scopus 로고
    • Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice
    • Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004; 113: 1763-1773.
    • (2004) J. Clin. Invest. , vol.113 , pp. 1763-1773
    • Cheung, W.C.1    Kim, J.S.2    Linden, M.3    Peng, L.4    Van Ness, B.5    Polakiewicz, R.D.6
  • 79
    • 0031984216 scopus 로고    scopus 로고
    • BCL-X expression in multiple myeloma: Possible indicator of chemoresistance
    • Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J et al. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res 1998; 58: 256-262.
    • (1998) Cancer Res. , vol.58 , pp. 256-262
    • Tu, Y.1    Renner, S.2    Xu, F.3    Fleishman, A.4    Taylor, J.5    Weisz, J.6
  • 80
    • 0036234124 scopus 로고    scopus 로고
    • MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis
    • Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16: 444-454.
    • (2002) Leukemia , vol.16 , pp. 444-454
    • Craig, R.W.1
  • 81
    • 0036699925 scopus 로고    scopus 로고
    • Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: Regulation during interleukin-6(IL-6)-induced growth and survival
    • Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol 2002; 69: 76-89.
    • (2002) Eur. J. Haematol. , vol.69 , pp. 76-89
    • Spets, H.1    Stromberg, T.2    Georgii-Hemming, P.3    Siljason, J.4    Nilsson, K.5    Jernberg-Wiklund, H.6
  • 82
    • 10744231548 scopus 로고    scopus 로고
    • Identification of genes modulated in multiple myeloma using genetically identical twin samples
    • Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103: 1799-1806.
    • (2004) Blood , vol.103 , pp. 1799-1806
    • Munshi, N.C.1    Hideshima, T.2    Carrasco, D.3    Shammas, M.4    Auclair, D.5    Davies, F.6
  • 83
    • 21744457447 scopus 로고    scopus 로고
    • Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
    • Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248-1252.
    • (2005) Leukemia , vol.19 , pp. 1248-1252
    • Wuilleme-Toumi, S.1    Robillard, N.2    Gomez, P.3    Moreau, P.4    Le Gouill, S.5    Avet-Loiseau, H.6
  • 84
    • 0038021146 scopus 로고    scopus 로고
    • A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells
    • Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22: 2950-2959.
    • (2003) Oncogene , vol.22 , pp. 2950-2959
    • Jourdan, M.1    Veyrune, J.L.2    Vos, J.D.3    Redal, N.4    Couderc, G.5    Klein, B.6
  • 85
    • 0037468570 scopus 로고    scopus 로고
    • IL-6-independent expression of Mcl-1 in human multiple myeloma
    • Zhang B, Potyagaylo V, Fenton RG. IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene 2003; 22: 1848-1859.
    • (2003) Oncogene , vol.22 , pp. 1848-1859
    • Zhang, B.1    Potyagaylo, V.2    Fenton, R.G.3
  • 86
    • 1642278407 scopus 로고    scopus 로고
    • Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells
    • Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, Grant S. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004; 103: 2761-2770.
    • (2004) Blood , vol.103 , pp. 2761-2770
    • Dai, Y.1    Pei, X.Y.2    Rahmani, M.3    Conrad, D.H.4    Dent, P.5    Grant, S.6
  • 87
    • 11144355586 scopus 로고    scopus 로고
    • BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
    • Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157.
    • (2004) Blood , vol.103 , pp. 3148-3157
    • Moreaux, J.1    Legouffe, E.2    Jourdan, E.3    Quittet, P.4    Reme, T.5    Lugagne, C.6
  • 88
    • 23044439051 scopus 로고    scopus 로고
    • Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
    • Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042-1047.
    • (2005) Blood , vol.106 , pp. 1042-1047
    • Raje, N.1    Kumar, S.2    Hideshima, T.3    Roccaro, A.4    Ishitsuka, K.5    Yasui, H.6
  • 89
    • 0142245593 scopus 로고    scopus 로고
    • Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
    • van de Donk NW, Kamphuis MM, Van Kessel B, Lokhorst HM, Bloem AC. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003; 102: 3354-3362.
    • (2003) Blood , vol.102 , pp. 3354-3362
    • van de Donk, N.W.1    Kamphuis, M.M.2    Van Kessel, B.3    Lokhorst, H.M.4    Bloem, A.C.5
  • 90
    • 2442674336 scopus 로고    scopus 로고
    • Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line
    • Pompeia C, Hodge DR, Plass C, Wu YZ, Marquez VE, Kelley JA et al. Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 2004; 64: 3465-3473.
    • (2004) Cancer Res. , vol.64 , pp. 3465-3473
    • Pompeia, C.1    Hodge, D.R.2    Plass, C.3    Wu, Y.Z.4    Marquez, V.E.5    Kelley, J.A.6
  • 91
    • 0035371644 scopus 로고    scopus 로고
    • Radiation-induced apoptosis in human myeloma cell line increases BCL-2/BAX dimer formation and does not result in BAX/BAX homodimerization
    • Filippovich IV, Sorokina NI, Lisbona A, Cherel M, Chatal JF. Radiation-induced apoptosis in human myeloma cell line increases BCL-2/ BAX dimer formation and does not result in BAX/BAX homodimerization. Int J Cancer 2001; 92: 651-660.
    • (2001) Int. J. Cancer , vol.92 , pp. 651-660
    • Filippovich, I.V.1    Sorokina, N.I.2    Lisbona, A.3    Cherel, M.4    Chatal, J.F.5
  • 93
    • 0035496921 scopus 로고    scopus 로고
    • Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma
    • Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M et al. Apo2L/ TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001; 98: 2183-2192.
    • (2001) Blood , vol.98 , pp. 2183-2192
    • Chen, Q.1    Gong, B.2    Mahmoud-Ahmed, A.S.3    Zhou, A.4    Hsi, E.D.5    Hussein, M.6
  • 94
    • 13244260526 scopus 로고    scopus 로고
    • Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms
    • Akay C, Thomas III C, Gazitt Y. Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms. Cell Cycle 2004; 3: 324-334.
    • (2004) Cell Cycle , vol.3 , pp. 324-334
    • Akay, C.1    Thomas III, C.2    Gazitt, Y.3
  • 95
    • 22144481007 scopus 로고    scopus 로고
    • SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
    • Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 2005; 106: 706-712.
    • (2005) Blood , vol.106 , pp. 706-712
    • Yasui, H.1    Hideshima, T.2    Hamasaki, M.3    Roccaro, A.M.4    Shiraishi, N.5    Kumar, S.6
  • 96
    • 0025120211 scopus 로고
    • Regulation of the mevalonate pathway
    • Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
    • (1990) Nature , vol.343 , pp. 425-430
    • Goldstein, J.L.1    Brown, M.S.2
  • 97
    • 0036045450 scopus 로고    scopus 로고
    • The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells
    • van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16: 1362-1371.
    • (2002) Leukemia , vol.16 , pp. 1362-1371
    • van de Donk, N.W.1    Kamphuis, M.M.2    Lokhorst, H.M.3    Bloem, A.C.4
  • 99
    • 0032404144 scopus 로고    scopus 로고
    • The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
    • Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294-5297.
    • (1998) Cancer Res. , vol.58 , pp. 5294-5297
    • Shipman, C.M.1    Croucher, P.I.2    Russell, R.G.3    Helfrich, M.H.4    Rogers, M.J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.